KemPharm
As Chief Scientific Officer, Dr. Guenther leads KemPharm’s research team and plays a central role in the advancement of the company’s pipeline of prodrugs and the development of new products that utilize KemPharm’s proprietary LAT® discovery technology to improve one or more of the attributes of approved drugs.
Prior to joining KemPharm, Dr. Guenther served as a research scientist for New River Pharmaceuticals, where he was part of the development team for Vyvanse®. He is an inventor on a number of patents and patent applications and author of several research papers.
Dr. Guenther received his Ph.D. degree from the University of Iowa.
This person is not in any offices
KemPharm
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product ...